ArrayPlex™ is Arrayjet’s patented discovery platform. With it, we can screen two libraries against each other using our unique multi-layered array platform which amplifies signal to noise. This takes high-throughput screening to the next level and generates hits without prior knowledge of either ligand or target.
ArrayPlex™ is made possible by the accuracy and speed of our contactless printing technology and the assay development expertise of our in-house microarray experts.
The platform is compatible with a broad combination of sample types and is ideal for…
In 2016 Arrayjet invented a novel therapeutic antibody screening assay for high-throughput discovery within a workflow where neither the antibody libraries nor the targets are characterised – this would become ArrayPlex™.
Immunome’s proprietary technology generates large libraries of hybridomas from patient B-cells, which are screened to discover novel targeted cancer therapies. Over a 7-year partnership, Arrayjet screened millions of interactions between antibodies and cancer tissue lysates for Immunome, all the while honing the assay.
In 2024 Immunome selected ArrayPlex™ for use in its discovery operations and ArrayPlex™ became available for new screening customers, with no exclusivity restrictions.
ArrayPlex™ was developed and validated for antibody discovery, but it is compatible with a broad combination of sample types. If you have two libraries you’d like to screen against each other, contact us for an expert consultation.